Phoqus Pharmaceuticals Ltd.

Last year was transformational for the Belgian biotech Ablynx. Not only did it sign the biggest product licensing deal of 2013 with AbbVie, it also further expanded its relationship with Merck Serono

The recent outpouring of soul searching, introspection and discussion prompted by the parting editorial from Greg Smith, a now ex-Goldman Sachs investment banker, has had little linkage to the biotech

Dr Patrick Round has been named chief medical officer and head of development at Xention, a UK biopharmaceutical company discovering and developing ion channel-modulating drugs. Dr Round has worked as

Phoqus Pharmaceuticals faces the ignominy of winding down its operations or selling itself after trading of its shares on AIM were suspended. The firm's failure to secure a commercial partner for it